About Tumor necrosis factor receptor superfamily member 4
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is a protein
from Homo sapiens identified by UniProt accession
P43489, 277 residues long.
MolForge cross-references it against 0 known binders and
371 disease associations.
Target properties
| Protein name | Tumor necrosis factor receptor superfamily member 4 |
|---|
| UniProt accession | P43489 |
|---|
| Gene | TNFRSF4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 277 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (371)
Diseases linked to this target (Open Targets).
- combined immunodeficiency due to OX40 deficiency · score 0.55
- atopic eczema · score 0.39
- Combined immunodeficiency · score 0.37
- combined immunodeficiency · score 0.37
- neurodegenerative disease · score 0.20
- blood protein measurement · score 0.16
- neoplasm · score 0.13
- acute myeloid leukemia · score 0.11
- infection · score 0.11
- infect · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P43489-F1 | alphafold | PREDICTED | 76.98 | — |
Amino-acid sequence (277 residues)
MCVGARRLGR GPCAALLLLG LGLSTVTGLH CVGDTYPSND RCCHECRPGN GMVSRCSRSQ NTVCRPCGPG FYNDVVSSKP CKPCTWCNLR SGSERKQLCT ATQDTVCRCR AGTQPLDSYK PGVDCAPCPP GHFSPGDNQA CKPWTNCTLA GKHTLQPASN SSDAICEDRD PPATQPQETQ GPPARPITVQ PTEAWPRTSQ GPSTRPVEVP GGRAVAAILG LGLVLGLLGP LAILLALYLL RRDQRLPPDA HKPPGGGSFR TPIQEEQADA HSTLAKI
Explore Tumor necrosis factor receptor superfamily member 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets